US-based biotech startup Solstice Biologics, which has an exclusive licence with University of California, San Diego, receives $18m series A investment.
Solstice Biologics, a San Diego-based biotech startup which has an exclusive licence for intellectual property covering RNA technologies from the University of California, San Diego (UoCSD), has received $18m in a series A round led by venture firm venBio, with participation from private equity fund Aeris Capital. It is the first such investment in the…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
